Streetwise Reports' Article Archives — January 2017 back to current month (4)
Inovio's Zika vaccine has demonstrated robust antigen-specific antibody responses in a Phase 1 study with 40 volunteers.
Why should investors keep an eye on these twenty small-cap biotechs in 2017? The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. 11.
Time to Go Long on BrainStorm Cell Therapeutics? (01/16/2017)
Jason Napodano of BioNap Consulting takes an in-depth look at BrainStorm Cell Therapeutics, including the science, the Phase 2 data and the potential valuation of the company developing adult stem cell-based therapies for neurodegenerative diseases.
Now in its fifth year, the 2017 Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco in January.
|"This looks like an excellent point to buy back VIV."|
|"PMN's stock is now showing signs that it is ready to advance anew."|
|"Data from DRRX's DUR-928 trial in AH showed meaningful improvements."|